Evaluation of the Effect of Pramlintide on Satiety and Food Intake

• Status: Completed
• Trial end date: 2003-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and obese non-diabetic subjects and in insulin-treated subjects with type 1 and type 2 diabetes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Islet Amyloid Polypeptide; Pramlintide

Criteria

For Healthy Volunteers:

•BMI >=20 to <=25kg/m2 or >=30 to <=40 kg/m2

For Subjects with Type 1 or Type 2 Diabetes:

• Treated with insulin for at least 6 months prior to screening

• HbA1c value between 6.5-10% inclusive

• BMI between 20-40kg/m2